Chinese pharma market primed for growth after sweeping reforms

China has carved itself a place as a major player in the pharma industry due to the number of clinical trials it is running, thanks to the reforms it has put in place.

As the world’s second-largest national pharmaceutical market in 2017, worth $122.6 billion, China was also the biggest emerging market for pharmaceuticals, with growth tipped to reach $145-175 billion by 2022, according to healthcare information firm IQVIA.